menu
    • menu
    [{"orgOrder":0,"company":"Edison Oncology","sponsor":"Apollomics Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"EO1001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edison Oncology \/ Apollomics","highestDevelopmentStatusID":"7","companyTruncated":"Edison Oncology \/ Apollomics"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Rakovina Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"EO2000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Edison Oncology \/ Rakovina Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Edison Oncology \/ Rakovina Therapeutics"},{"orgOrder":0,"company":"Edison Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Edison Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Edison Oncology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Edison Oncology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Edison Oncology

    Menu

    Edison Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Edison Oncology

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Edison Oncology

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Irinotecan Hydrochloride,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Edison Shares Promising Interim Data from Ongoing Orotecan® Trial for Pediatric Cancers

                            Details : Orotecan (irinotecan HCl) is a topoisomerase-I inhibitor approved by the FDA. It is now being evaluated for the treatment of recurrent pediatric solid tumors.

                            Brand Name : Orotecan

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2024

                            Lead Product(s) : Irinotecan Hydrochloride,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Edison Oncology

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Edison Oncology

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EO2000

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Rakovina Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics

                            Details : Edison Oncology Holding Corp. has transferred certain rights to novel DNA-damage response inhibitors, including its EO2000 series PARP Inhibitor Program Technology, to Rakovina Therapeutics Inc.

                            Brand Name : EO2000

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 31, 2021

                            Lead Product(s) : EO2000

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Rakovina Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Edison Oncology

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Edison Oncology

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EO1001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Apollomics Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor ...

                            Details : Under the terms of the agreement, Apollomics has the exclusive rights to develop and commercialize EO1001 globally, except in China, Hong Kong and Taiwan.

                            Brand Name : EO1001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 09, 2021

                            Lead Product(s) : EO1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Apollomics Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth